Fortunately, the advent of immune checkpoint inhibitors has improved the outlook for patients with advanced lung cancers. Tumor immunotherapy targeting PD-1/PD-L1 have revolutionized the treatment of lung cancer (70, 72, 90). The gene discussed is CD274; the disease is lung carcinoma.